MORGAN STANLEY PLC/CALL/EDWARDS LIFESCIENCES/120/0.1/20.12.24 | Market Closed - Börse Stuttgart 17:36:10 07/06/2024 BST | ||
| 0.158 EUR | +1.28% |
|
| Current month | +12.86% | ||
| 1 month | +53.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 0.158 | +1.28% |
| 06/06/24 | 0.156 | +4.70% |
| 05/06/24 | 0.149 | +4.93% |
| 04/06/24 | 0.142 | -4.05% |
| 03/06/24 | 0.148 | +5.71% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 05:36 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | Morgan Stanley |
| WKN | MB8GN7 |
| ISIN | DE000MB8GN72 |
| Date issued | 07/07/2023 |
| Strike | 120 $ |
| Maturity | 20/12/2024 (196 Days) |
| Parity | 10 : 1 |
| Emission price | 0.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.6 € |
|---|---|
| Lowest since issue | 0.084 € |
| Spread | 0.01 € |
| Spread % | 5.92% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
88.14
USD
Average target price
96.31
USD
Spread / Average Target
+9.27%
- Stock Market
- Warrants
- Warrant